Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
CSL Limited
With
Parexel
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Male or female aged 18 years or older.
Previous diagnosis of CD123+ acute myeloid leukemia (AML), de novo or secondary.
Completed and recovered from all planned induction and consolidation therapy according to the institution's standard of care, and achieved a complete remission (CR)/CR with incomplete platelet recovery (CRp); either first or second CR.
Has factors conferring high risk of relapse.
No plans for additional post-remission chemotherapy.
Not currently a candidate for allogeneic hematopoietic stem cell transplant (HSCT).
You may not be if
Diagnosis of acute promyelocytic leukemia (APL).
Known leukemic involvement of the central nervous system.
Life expectancy 4 months or less as estimated by the investigator.
Concurrent treatment or planned treatment with other anticancer therapy (chemotherapy, immunotherapy, radiotherapy, targeted therapy, gene therapy).
Clareo Health | A Study of CSL362 in Patients With CD123+ Acute Myeloid Leukemia Currently in Remission
